Nabiximols | CAS# 56575-23-6 | THC/CBD Combination

MedKoo Cat#: 564342 | Name: Nabiximols

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nabiximols is a delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) combination for the treatment of multiple sclerosis (MS) related moderate to severe spasticity.

Chemical Structure

Nabiximols

CAS#56575-23-6

Theoretical Analysis

MedKoo Cat#: 564342

Name: Nabiximols

CAS#: 56575-23-6

Chemical Formula: C42H60O4

Exact Mass: 628.4492

Molecular Weight: 628.94

Elemental Analysis: C, 80.21; H, 9.62; O, 10.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

GW1000; GW 1000; GW-1000; SAB-378; SAB 378; SAB378; Sativex; Nabiximols

IUPAC/Chemical Name

(6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

InChi Key

SSNHGLKFJISNTR-FWUPRJFYSA-N

InChi Code

InChI=1S/2C21H30O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15;1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,16-17,22H,5-10H2,1-4H3;11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t16-,17-;17-,18?/m10/s1

SMILES Code

OC1=CC(CCCCC)=CC2=C1[C@@](C=C(C)CC3)([H])[C@]3([H])C(C)(C)O2.OC4=CC(CCCCC)=CC(O)=C4C5C=C(C)CC[C@H]5C(C)=C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 628.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sorosina M, Clarelli F, Ferrè L, Osiceanu AM, Unal NT, Mascia E, Martinelli V, Comi G, Benigni F, Esposito F, Martinelli Boneschi F. Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol. 2018 Jul;25(7):934-e70. doi: 10.1111/ene.13623. Epub 2018 Apr 16. PubMed PMID: 29528549. 2: Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2. PubMed PMID: 29776349; PubMed Central PMCID: PMC5960200. 3: Castelli L, Prosperini L, Pozzilli C. Balance worsening associated with nabiximols in multiple sclerosis. Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649. [Epub ahead of print] PubMed PMID: 29533137. 4: Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. J Pain Symptom Manage. 2018 Feb;55(2):179-188.e1. doi: 10.1016/j.jpainsymman.2017.09.001. Epub 2017 Sep 18. PubMed PMID: 28923526. 5: Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018. PubMed PMID: 29385147; PubMed Central PMCID: PMC5791962. 6: Kanaan AS, Jakubovski E, Müller-Vahl K. Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci. 2017 Apr 26;7(5). pii: E47. doi: 10.3390/brainsci7050047. PubMed PMID: 28445405; PubMed Central PMCID: PMC5447929.